Home » Topics » BioWorld Science, Neurology/psychiatric

BioWorld Science, Neurology/psychiatric
RSS

Elan subsidiary obtains patent rights for Cytel's integrin-blocking antibodies

Aug. 19, 1998

The Medicines Company acquires clinical-stage antimigraine drug for development

Aug. 18, 1998

Eisai files for Japanese approval of AD treatment agent

Aug. 17, 1998

Gidazepam, a new benzodiazepine anxiolytic with potential in asthenic disorders

Aug. 17, 1998

Unique agent for cognition disorders: GTS-21, a nicotinic acetylcholine agonist

Aug. 17, 1998

New cerebroprotective agents described by Japanese team

Aug. 17, 1998

Muscle-relaxant activity of silperisone: comparison with lidocaine

Aug. 14, 1998

Analben, a non-narcotic analgesic in phase II testing

Aug. 14, 1998

Known antiischemic agent demonstrates cognition-enhancing effects

Aug. 14, 1998

Three studies confirm efficacy and safety of Chinese AD treatment agent

Aug. 14, 1998

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 31, 2026.
New schizophrenia targets challenge trial design
BioWorld
The search for better schizophrenia therapies is moving beyond dopamine toward a growing number of experimental targets. According to researchers, the repeated...
AIDS 2026: New targets for metabolic dysfunction despite ART
BioWorld
Although antiretroviral therapy (ART) can suppress HIV to undetectable levels, a growing body of evidence suggests that the virus leaves a lasting biological...
News in brief
BioWorld Asia
BioWorld Asia briefs for July 28, 2026
Jingxin discloses new muscarinic and sigma receptor agonists
BioWorld Science
Shanghai Jingxin Biopharmaceutical Co. Ltd. and Zhejiang Jingxin Pharmaceutical Co. Ltd. have synthesized new muscarinic acetylcholine receptor and sigma receptor...